Evidence
JACC Basic Transl Sci. 2023 Sep 13;8(10):1334-1353. doi: 10.1016/j.jacbts.2023.06.005. eCollection 2023 Oct.
ABSTRACT
Cardiovascular diseases (CVDs) are the leading cause of death among elderly people. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important regulator of cholesterol metabolism. Herein, we investigated the role of PCSK9 in age-related CVD. Both in humans and rats, blood PCSK9 level correlated positively with increasing age and the development of cardiovascular dysfunction. Age-related fatty degeneration of liver tissue positively correlated with serum PCSK9 levels in the rat model, while development of age-related nonalcoholic fatty liver disease correlated with cardiovascular functional impairment. Network analysis identified PCSK9 as an important factor in age-associated lipid alterations and it correlated positively with intima-media thickness, a clinical parameter of CVD risk. PCSK9 inhibition with alirocumab effectively reduced the CVD progression in aging rats, suggesting that PCSK9 plays an important role in cardiovascular aging.
PMID:38094682 | PMC:PMC10715889 | DOI:10.1016/j.jacbts.2023.06.005
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction
🌐 365 Days
VR Related Evidence Matrix
